NCT03624010Phase 2Completed

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

Study sponsor: Tenax Therapeutics, Inc. · TENX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-04-25Actual
Enrollment · participants35Actual
Source updated2026-04-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Clinical Safety measured by number of adverse events (AEs ). After: Measure: Clinical Safety.

Actual enrollment increased by 15 participants

Before: 20 participants (actual). After: 35 participants (actual).

Primary completion date changed

Before: 1 Feb 2024. After: 25 Apr 2023.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview